| Symbol | BDTX |
|---|---|
| Name | BLACK DIAMOND THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE MAIN STREET,10TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 252-0848 |
| Fax | — |
| — | |
| Website | https://www.blackdiamondtherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001701541 |
| Description | Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. Additional info from NASDAQ: |
Behbahani Ali 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 288598
Read moreKulkarni Samarth 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 000002
Read moreMenzel Garry E 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 000002
Read moreRaman Prakash 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 000012
Read moreDhingra Kapil 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 000002
Read moreCampbell Shannon 🟢 acquired 40.0K shares (1 derivative) of Black Diamond Therapeutics, Inc. (BDTX) at $1.71 Transaction Date: Jun 26, 2026 | Filing ID: 000007
Read more(99% Neutral) BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Announces Regulatory Update
Read moreBehbahani Ali 🟢 acquired 9.0K shares of Black Diamond Therapeutics, Inc. (BDTX) at $1.66 Transaction Date: Jun 19, 2026 | Filing ID: 277553
Read moreRaman Prakash 🟢 acquired 7.9K shares of Black Diamond Therapeutics, Inc. (BDTX) at $1.66 Transaction Date: Jun 19, 2026 | Filing ID: 000008
Read moreBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GB… | Phase2 | Glioblastoma (GBM) | Recruiting | 2026-05-05 | 2029-03-01 | ClinicalTrials.gov |
| NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or No… | Phase1 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2022-03-31 | 2027-12-01 | ClinicalTrials.gov |
| NCT04209465 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients… | Phase1 | Solid Tumor | Terminated | 2019-12-19 | 2022-09-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib (BDTX-1535) monotherapy | Drug | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05256290 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| BDTX-189 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04209465 |
| silevertinib (BDTX-1535) monotherapy | Drug | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05256290 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | Other | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| temozolomide (TMZ) | DRUG | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | DRUG | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib (BDTX-1535) monotherapy | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05256290 |
| BDTX-189 | DRUG | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04209465 |